Research last month suggested that starting GLP-1 receptor agonist treatment in people with epilepsy and type 2 diabetes was ...

Popular GLP-1 medications such as Ozempic may carry an unexpected link to a lower risk of epilepsy in people with type 2 ...

A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk of developing epilepsy. The study was published on December 10, 2025, in ...

In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction through the study's 52-week ...

About one in eight adults say they are taking a GLP-1 receptor agonist as a treatment for obesity, diabetes or another ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes medications — also known as GLP-1 and GIP injections — are changing the way we ...

VANCOUVER, BC / ACCESS Newswire / December 11, 2025 / LIR Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") announces that it has filed a provisional patent applicat ...

A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed promising results in new data released Thursday by its maker, Eli Lilly.

A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk ...

Tirzepatide is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human brain ...

A large US database study suggests GLP-1 receptor agonists may be associated with a reduced risk of developing epilepsy in ...